NAMSA, a world-leading MedTech Contract Research Organisation (CRO) offering global end-to-end development services, has announced the acquisition of Perfectus Biomed Group, the Sci-Tech Daresbury located business specialising in customised microbiological services.  

As the global leader of the medical device testing industry since 1967, NAMSA has amassed a large breadth and depth of therapeutic expertise and knowledge across the full spectrum of microbiology and in vitro testing services. NAMSA’s world-class testing capabilities include all areas of microbiological sterility, validation and quality assurance solutions in its well-equipped facilities in the U.S. and France. 

Perfectus Biomed Group – located at Techspace One at the Sci-Tech Daresbury campus – is a CRO focused on customised testing that supports its clients’ vision throughout their product development and regulatory journeys. 

Specialist services offered by Perfectus Biomed Group includes accredited biofilm testing, microbiology, molecular biology, cell culture and virology. These services are used to support companies in the medical device, wound care, biocide, cosmetic and pharmaceutical sectors. 

Perfectus Biomed Group’s customers will continue to receive the quality they have come to know and expect but with access to a unified, wider spectrum of industry experience and increased testing capabilities. 

Sam Westgate, Perfectus Biomed Group CEO said: “Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver best-in-class global MedTech solutions through its people, expertise and technology. With similar values and expertise to customise solutions for clients across the globe, we are well aligned to achieve future success for both our clients and combined organisations. 

“With the complimentary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and we look forward to joining the world’s leading CRO for full continuum development services.”  

Dr. Christophe Berthoux, NAMSA CEO, said: “NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group. 

“Perfectus brings an unmatched level of expertise and depth of knowledge in customised microbiological testing solutions. This know-how and extreme proficiency in microbiological research will help us to further support Clients and continue to provide cutting-edge solutions for medical device testing and research.”  

John Leake, business growth director, Sci-Tech Daresbury: “Since joining us as a start-up company, Sam and her team have demonstrated what can be achieved when world-leading expertise is married with innovation, an ambitious business model and the supportive and collaborative business community at Sci-Tech Daresbury. 

“The manner in which the company has grown in recent years is inspirational, and this acquisition by NAMSA means even more clients across the world will benefit from the expertise and innovation nurtured by Perfectus Biomed Group right here in the Liverpool City Region.” 

Perfectus Biomed was established in 2012 by CEO Dr Sam Westgate and in 2020 merged with US based laboratory Extherid Biosciences LLC, forming Perfectus Biomed Group.